EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non‐small‐cell lung cancer with bone metastasis

Yohei Asano iD, Norio Yamamoto iD, Satoru Demura, Katsuhiro Hayashi, Akihiko Takeuchi, Satoshi Kato iD, Shinji Miwa iD, Kentaro Igarashi, Takashi Higuchi iD, Yuta Taniguchi, Sei Morinaga, Takashi Sone und 4 weitere

Cancer Medicine · 2023

DOI: 10.1002/cam4.5952 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Medicine, 2023. Verfasst von Yohei Asano und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Orthopaedic Surgery, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Bone Neoplasms. Die Arbeit wurde bisher 20-mal zitiert (Crossref) und nennt 63 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Backgrounds Immune checkpoint inhibitors (ICIs) can significantly prolong the survival of patients with advanced non‐small‐cell lung cancer (NSCLC); however, few studies on the therapeutic effects of ICIs on bone metastases were performed.

Methods

This retrospective study aimed to investigate the therapeutic effects of ICIs and determine predictors of favorable ICI response and prognosis in 55 advanced NSCLC patients with bone metastases who initiated ICI treatment between 2016 and 2019, with a mean follow‐up period of 23.2 months. Patients were classified into responders (complete or partial response) and non‐responders (stable or progressive disease) according to the MD Anderson Cancer Center (MDA) criteria, and the predictors of therapeutic response were identified using multivariate logistic regression analysis. Furthermore, overall survival from the time of ICI administration to the final follow‐up or death was evaluated, and prognostic predictors were identified using Cox proportional hazards regression analysis.

Results

ICI response rate was 30.9% (complete in three cases, partial in 14). Median survival time was 9.3 months, with 1‐year and 2‐year survival rates of 40.6% and 19.3%, respectively. Responders survived significantly longer than non‐responders ( p = 0.03). Based on the receiver operating characteristic curve, the predictive cutoff value of the pretreatment neutrophil‐to‐lymphocyte ratio (NLR) was 2.1. Multivariate analysis identified female sex ( p = 0.03), use of ICIs as first‐line therapy ( p < 0.01), and NLR

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungLung NeoplasmsBone NeoplasmsHumansFemaleImmune Checkpoint InhibitorsRetrospective StudiesPrognosis

Stichwörter der Autor:innen

bone metastasisdenosumabimmune checkpoint inhibitorneutrophil-to-lymphocyte rationon-small-cell lung cancer

Substanzen

Immune Checkpoint Inhibitors

Autor:innen und Institutionen

  • Department of Orthopaedic Surgery, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
  • Department of Respiratory Medicine, Kanazawa University Hospital, Kanazawa, Japan.
  • Department of Respiratory Medicine, Ishikawa Prefectural Central Hospital, Kanazawa, Japan.
  • Department of Radiology, Kanazawa University Graduate School of Medical Sciences, Kanazawa, Japan.
  • Department of Thoracic Surgery, Kanazawa University, Kanazawa, Japan.

ORCID-Profile: Yohei Asano, Norio Yamamoto, Satoshi Kato, Shinji Miwa, Takashi Higuchi

Zitieren

APA

Asano, Y., Yamamoto, N., Demura, S., Hayashi, K., Takeuchi, A., Kato, S., Miwa, S., Igarashi, K., Higuchi, T., Taniguchi, Y., Morinaga, S., Sone, T., Okuda, M., Matsumoto, I., Yano, S., & Tsuchiya, H. (2023). Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non‐small‐cell lung cancer with bone metastasis. Cancer Medicine. https://doi.org/10.1002/cam4.5952

Vancouver

Asano Y, Yamamoto N, Demura S, Hayashi K, Takeuchi A, Kato S, et al. Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non‐small‐cell lung cancer with bone metastasis. Cancer Medicine. 2023. doi:10.1002/cam4.5952

BibTeX
@article{Asano2023,
  author = {Asano, Yohei and Yamamoto, Norio and Demura, Satoru and Hayashi, Katsuhiro and Takeuchi, Akihiko and Kato, Satoshi and Miwa, Shinji and Igarashi, Kentaro and Higuchi, Takashi and Taniguchi, Yuta and Morinaga, Sei and Sone, Takashi and Okuda, Miho and Matsumoto, Isao and Yano, Seiji and Tsuchiya, Hiroyuki},
  title = {Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non‐small‐cell lung cancer with bone metastasis},
  journal = {Cancer Medicine},
  year = {2023},
  doi = {10.1002/cam4.5952}
}
Kostenlos starten →